115956-07-5

Basic information

• Product Name: (2a,6a,8a,9ab)-Hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one
• Synonyms: ENDO-HEXAHYDRO-HYDROXY-2,6-METHANO-2H-QUINOLIZIN-3-(4H)-ONE;(2A,6A,8A,9AB)-, HEXAHYDRO-8-HYDROXY-, 2,6-METHANO-2H-QUINOLIZIN-3(4H)-ONE;Endo-Hexahydro-8-Hydroxy-2,6-Methano-2h-Quinolizin-3(4h)-One;(2α,6α,8α,9αβ)-Hexahydro-8-hydroxy-2,6-methano-2H-quinoliz;INTERMEDIATE OF DOLASETRON;Hexahydro-8-hydroxy-2,6-methano-2H-quinolizin(4H)-one;(2A,6A,8A,9AB)-,HEXAHYDRO-8-HYDROXY-,2,6-METHANO-2H-QUINOLIZIN-3(4H)-ONE(INTERMEDIATEOFDOLASETRON);(2α, 6α, 8α, 9αβ) hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one
• CAS NO: 115956-07-5
• Molecular Formula: C10H15NO2
• Molecular Weight: 181.23
• Product Categories: INTERMEDIATESOFDOLASETRONMESYLATE;(intermediate of dolasetron)
• Mol File: 115956-07-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 356°C
• Flash Point: 169°C
• Appearance: /
• Density: 1.28
• Vapor Pressure: 1.67E-06mmHg at 25°C
• Refractive Index: 1.589
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (2a,6a,8a,9ab)-Hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: (2a,6a,8a,9ab)-Hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one(115956-07-5)
• EPA Substance Registry System: (2a,6a,8a,9ab)-Hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one(115956-07-5)

Safety Data

• Hazardous Substances Data: 115956-07-5(Hazardous Substances Data)

Usage

Chemical Properties

White or light yellow crystalline

InChI:InChI=1/C10H15NO2/c12-9-3-7-1-6-2-8(4-9)11(7)5-10(6)13/h6-9,12H,1-5H2/t6?,7-,8+,9+

Upstream product

• 889135-54-0 7-ethoxycarbonyl-9-(ethoxycarbonyl-methyl)-3-(2-tetrahydro-2H-pyranyloxy)-9-azabicyclo[3.3.1]nonane methanesulfonate 
• 125483-30-9 tetrahydropyranyl ether of 7-methoxycarbonyl-9-(methoxycarbonylmethyl)-9-azabicyclo[3.3.1]nonan-3-ol 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 115956-12-2 endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-one 
• 115956-13-3 dolasetron mesylate 
• 139014-62-3 indole-3-carboxylic acid octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester 
• 115956-12-2 trans-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-one base 
• 115956-12-2 dolasetron 
• 115956-12-2 dolasetron 
• 115956-13-3 dolasetron mesylate 

Relevant articles and documents

Dolasetron mesylate crystal form and preparation method

The invention provides a dolasetron mesylate crystal form. The molecular structural formula is represented in the description. The crystal form is a white powdery crystal, molecular composition is C19H20N2O3.CH3SO3H.H2O, a reflection angle 2 theta of X-ray powder diffraction of the crystal form has characteristic peaks at 11.8 degrees, 12.1 degrees, 15.1 degrees, 15.4 degrees, 22.9 degrees, 26.6 degrees, 29.9 degrees and 30.1 degrees, and differential scanning calorimetry shows that three absorption peaks exist at 150 DEG C, 164 DEG C and 260 DEG C. According to the dolasetron mesylate crystalform, product purity is high, few single impurities are contained, and heat stability of the crystal form is good. The invention further provides a preparation method of the dolasetron mesylate crystal form.

PRODUCTION OF DOLASETRON

The present invention provides an improved process for the preparation of Dolasetron salts, in particularly Dolasetron mesylate. % Also provided are intermediates for the process and methods of preparing the intermediates.

Use of certain esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolozin-3(4H)-one and related compounds for treating cognitive disorders

This invention relates to the manufacture of certain esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and hexahydro-8-hydroxy-2,6-methano-2H-quinolizines and their use as medicaments in the treatment of cognitive disorders.